AzTrials
AzTrials

Cancer, OtorhinolaryngealRADEFILACNCT06604494

Rehabilitation Improved by Early Detection of Fisyulas Post (Pharyngo) -Total Laryngectomy by Cytokine Measurement on Drainage Fluid on the Second Post-Operative Day

A study testing early feeding resumption and late feeding resumption in people with Cancer, Otorhinolaryngeal, run by University Hospital, Clermont-Ferrand at 7 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Post-pharyngo-laryngectomy fistula is a frequent surgical complication, resulting in delayed patient management and reduced quality of life. A recent study has shown that the appearance of a fistula can be detected early by measuring cytokines (particularly IL10) in postoperative drainage fluids. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Cancer, Otorhinolaryngeal
What is being tested?
early feeding resumption and late feeding resumption
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
250 participants
Where
7 sitesFrance
Study dates
12 Feb 2025to May 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patient with cancer requiring a total laryngectomy or pharyngolaryngectomy scheduled after multidisciplinary consultation.
  • Holder of a social security scheme

Who cannot join

  • Pregnant and breastfeeding women Persons under curatorship, guardianship, legal protection or deprived of liberty Any medical condition deemed by the investigator to be incompatible with the study. Refusal to participate. Body mass index less than 18.5 kg/ m2
  • -

Trial locations and contacts

7 sites in 1 country. Contact the study team or a site near you to ask about taking part.

7 sites in 1 country

France7 sites, 7 recruiting
  • CHU de Clermont-Ferrand

    Clermont-Ferrand

    Lise Laclautre

    Nicolas Saroul

    Recruiting
  • CHU de Grenoble

    Grenoble

    Lise Laclautre

    Fabre Christol

    Not yet recruiting
  • CH Emile Roux

    Le Puy-en-Velay

    Lise Laclautre

    Marc Durand

    Not yet recruiting
  • HCL Hôpital Croix Rousse

    Lyon

    Lise Laclautre

    Philippe CERUSE

    Not yet recruiting
  • CHU de Saint-Etienne

    Saint-Etienne

    Lise Laclautre

    Yann Lelonge

    Not yet recruiting
  • CH de Valence

    Valence

    Lise Laclautre

    Guillaume Buiret

    Not yet recruiting
  • Institut Gustave Roussy

    Villejuif

    Lise Laclautre

    Ingrid Breuskin

    Not yet recruiting

Other trials in France

About this study

Post-pharyngo-laryngectomy fistula is a frequent surgical complication, resulting in delayed patient management and reduced quality of life. A recent study has shown that the appearance of a fistula can be detected early by measuring cytokines (particularly IL10) in postoperative drainage fluids. Resumption of feeding following this surgery varies between postoperative day 5 and postoperative day 15, depending on the team\'s habits. Early refeeding reduces the length of hospital stay and improves patients\' quality of life. The decision to refeed is currently made without any clinical or biological marker of the quality of pharyngeal suture healing. The idea of this study is that good initial healing (evidenced by low levels of inflammatory cytokine in drainage fluids) allows early refeeding without putting the patient at additional risk.

Main hypothesis and research objectives Main hypothesis: the determination of cytokines in postoperative drainage fluids (FODP) could be a tool for screening patients at no risk of developing a fistula, and for whom early refeeding (as early as postoperative day 3) could be proposed without exposing the patient to an additional risk of developing a FODP.

Read more

Study objectives Primary objective: to compare the rate of post-(pharyngo)-total laryngectomy fistula between an early refeeding strategy (3rd or 4th postoperative day) and a late refeeding strategy (current standard of care: 7th postoperative day) in a low-risk fistula group defined according to the level of inflammatory cytokines in drainage fluids on the second postoperative day.

Secondary objectives

To compare an early versus a late refeeding strategy for patients at low risk of fistula defined according to the level of inflammatory cytokines in drainage fluids on the second postoperative day for:

  • length of hospital stay,
  • evolution of nutritional status,
  • time to postoperative radio-chemotherapy, if indicated postoperatively,
  • improvement in quality of life,
  • post-operative complications other than pharyngeal fistula. Evaluation of different strategies left to the investigator\'s choice (continuation of antibiotic therapy, increased delay before resumption of feeding, early resumption of surgery) in the group of patients at high risk of fistula, based on the determination of postoperative cytokines in drainage fluids.

Primary endpoint: Pharyngo-cutaneous fistula occurring within 30 days post-operatively (yes/no).

Number of subjects: 250 Inclusion criteria Major cancer patient justifying scheduled total laryngectomy or pharyngo-laryngectomy after multidisciplinary consultation.

Holder of a social security plan. Non-inclusion criteria Pregnant and breast-feeding women Persons under curatorship, guardianship, safeguard of justice or deprived of liberty.

Any medical condition deemed incompatible with the study by the investigator. Refusal to participate. Body mass index less than 18.5 kg/m2

Read the detailed description

Course of the study Patients will be recruited from the ENT departments of the Clermont Ferrand, Saint-Etienne, Lyon and Grenoble university hospitals, the Lyon (Centre Léon Bérard) and Paris (Institut Gustave Roussy) cancer centers, and the Le Puy En Velay and Valence hospitals, all of which are accredited for cervico-facial carcinology.

A multidisciplinary consultation meeting will be required to validate the surgical procedure.

Patients will be informed of the study by the investigating physician. After a period of reflection and a chance to answer any questions, the patient will be included in the study after consent has been obtained from an investigator.

The main risk factors for the development of a fistula will be recorded pre- and intraoperatively.

Surgical criteria will be common to all investigating teams. The most important of these will be the positioning of the LDPO collection drain opposite the pharyngeal closure site. The drain may or may not be aspirative, depending on local habits. The concomitant insertion of a phonatory prosthesis or a salivary bypass are not grounds for exclusion.

Post-operative care must meet precise specifications. Drainage fluids will be collected from the drainage bottle on D2 post-op. To do this, the entire drainage bottle will be recovered, and a new bottle will be placed over the drain if the drain is retained.

The liquid contained in the drainage bottle is then sterile-separated into different samples directly in the patient\'s hospital ward:

  • Immunological sampling. A BD Falcon™ Conical Tubes 50 mL will be sent to the immunology laboratory associated with the investigating center (Clermont-Ferrand University Hospital Immunology Laboratory for the Clermont-Fd and Le Puy en Velay sites, Lyon University Hospital Immunology Laboratory for the Grenoble, Lyon, Valence and Lyon anti-cancer center, the immunology laboratory of the Assistance Publique Hopitaux de Paris for the Gustave Roussy Institute and the immunology laboratory for the Saint-Etienne center). The sample is then centrifuged at 3,000 rpm for 10 minutes at 4°C.a "high-risk" group for CPE.
  • Bacteriological sampling. This sample will be sent rapidly to the bacteriology laboratory of the investigating center for standard cyto-bacteriological analysis.

For an IL 10 level on D2 post-op of less than 72pg/mL (so-called low-risk fistula group defined from the DEFILAC pilot study), two groups of patients will be constituted:

Low-risk fistula group: OPT performed on D3 or D4 (before randomization and after IL-10 results). If TPO classified according to van la Parra ≤1, patients will be randomized into 2 groups:

  • "EARLY" group: Resumption of feeding on postoperative day 3 or 4 with a liquid or mixed diet.
  • "TARDIF" group: return to a mixed diet from day 7 post-op. Randomization will be centralized, computerized with random block sizes, stratified by center and patient age.

If the TOP shows images classified according to van la Parra\>1, patients will join the so-called high-risk CPE exploratory arm.

If IL10 levels on D2 post-op exceed 72 pg/mL (high-risk group for post-op fistula), these patients will form a third, exploratory group, whose management will be left to the investigator\'s choice, with 3 possibilities (no change in investigators\' habits): repeat surgery to clean the surgical site and repair the pharyngeal sutures, broad-spectrum antibiotic therapy while awaiting the bacteriological results of the cytobacteriological examination of the drainage fluid on postoperative day 2, without repeat surgery, monitoring and no change in the investigator\'s routine.

Postoperative complications will then be noted and classified according to the Clavien-Dindo classification over a period of 30 postoperative days.

The appearance of a salivary fistula at the tracheostoma will be objectified by the appearance of saliva in the tracheostoma. The appearance of a fistula at the cervical level will be sought either by imaging methods in the event of a cervical complication (infection, hemorrhage) if no surgical revision is decided and surgically by loss of sealing confirmed surgically if a revision is necessary.

The appearance of a subsequent fistula will be noted. The patient will have a final consultation 30 days after surgery if he or she is no longer hospitalized.

The quality of life of the patients will be assessed throughout the study by completing an anxiety questionnaire and a depression questionnaire. This assessment will be done before surgery, on D5, D15 and D30 of surgery. Before surgery and at D5, these questionnaires will be completed during hospitalization. At D15 and D30, the questionnaires will be completed during hospitalization if the patient is still hospitalized or by mail if the patient has been discharged from the surgical department having performed the pharyngolaryngectomy procedure. The date of the start of chemoradiotherapy will then be noted and the time between surgery and the start of this treatment will be noted.

Being tested
early feeding resumption, late feeding resumption
Keywords
total laryngectomy
Medical subject headings
Otorhinolaryngologic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • early feeding resumptionBehavioural

    Resumption of food on the 3rd or 4th day post-operatively with a mixed diet.

  • late feeding resumptionBehavioural

    Resumption of food on the 7th day post-operatively with a mixed diet.

Study groups in NCT06604494
Study groupRoleWhat they receive
Early groupExperimentalFor an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet.
Receives: Behavioral: early feeding resumption
late groupPlacebo comparatorFor an IL 10 level on postoperative day 2 below 72 pg/mL (group said to be at low risk of developing a fistula defined from the DEFILAC pilot study), resumption of food on the 3rd or 4th postoperative day with a mixed diet.
Receives: Behavioral: late feeding resumption
No interventionNo interventionFor an IL 10 level on postoperative day 2 greater than 72 pg/mL (group at high risk of postoperative fistula), these patients will constitute a third, exploratory group, whose management will be left to the investigator's discretion.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pharyngocutaneous fistula occurring within 30 days postoperatively

    Apparition or not of Pharyngocutaneous fistula occurring within 30 days postoperatively (yes/no).

    Measured: Day 30

Secondary outcomes (23)
  1. Hospitalization time in days.

    Duration of Hospitalization time in days.

    Measured: Day 30

  2. Evolution of Weight in kg

    Evolution of nutritional status between the start and the end of hospitalization assessed by the evolution of weight, strength of the forearm (Hand grip strength test)

    Measured: Day 30

  3. Nutrition Risk INdex

    Evolution of nutritional status between the start and the end of hospitalization assessed by the evolution of the Nutrition Risk Index (NRI),

    Measured: Day 30

  4. Measure of grip strenght

    Evolution of nutritional status between the start and the end of hospitalization assessed by the evolution of the grip strength of the forearm (Hand grip strength test)

    Measured: Day 30

  5. Deadlines for the implementation of post-operative radio-chemotherapy

    Deadlines for the implementation of post-operative radio-chemotherapy

    Measured: Day 30

  6. Clavien-Dindo Classification

    Surgical complications within 30 days post-operatively by the Clavien-Dindo classification

    Measured: Day 30

  7. Beck Depression Inventory II questionnaire

    Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire

    Measured: Day 0

  8. Beck Depression Inventory II questionnaire

    Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire

    Measured: Day 5

  9. Beck Depression Inventory II questionnaire

    Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire

    Measured: Day 15

  10. Beck Depression Inventory II questionnaire

    Quality of life, measure of level of depression by Beck Depression Inventory II questionnaire

    Measured: Day 30

  11. Beck Anxiety Inventory

    Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire

    Measured: Day 0

  12. Beck Anxiety Inventory

    Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire

    Measured: Day 5

  13. Beck Anxiety Inventory

    Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire

    Measured: Day 15

  14. Beck Anxiety Inventory

    Quality of life, measure of level of anxiety by BBeck Anxiety Inventory questionnaire

    Measured: Day 30

  15. EORTC-QLQ30 questionnaire

    Measure of quality of life by EORTC-QLQ30 questionnaire

    Measured: Day 0

  16. EORTC-QLQ30 questionnaire

    Measure of quality of life by EORTC-QLQ30 questionnaire

    Measured: Day 5

  17. EORTC-QLQ30 questionnaire

    Measure of quality of life by EORTC-QLQ30 questionnaire

    Measured: Day 15

  18. EORTC-QLQ30 questionnaire

    Measure of quality of life by EORTC-QLQ30 questionnaire

    Measured: Day 30

  19. Tumor status

    Tumor status by TNM classification 8th edition

    Measured: Day 30

  20. Cytobacteriological examination of the drainage fluid.

    Cytobacteriological examination of the drainage fluid.

    Measured: Day 2

  21. continuation of antibiotic therapy

    continuation of antibiotic therapy (in days)

    Measured: Day 30

  22. Resuming food

    increase in time before resuming food

    Measured: Day 30

  23. Surgical resumption

    early surgical resumption and type of procedure performed in the group of patients with no intervention

    Measured: Day 30

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2024
  2. Study start12 Feb 2025
  3. Primary completionMay 2028 (estimated)
  4. Study completionMay 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
250 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06604494
Sponsor's protocol ID
PHRCI 2022 SAROUL
Other IDs
2024-A00652-45
Acronym
RADEFILAC
Status last verified
Mar 2025
First submitted
17 Sep 2024
Last updated
22 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing early feeding resumption and late feeding resumption in people with Cancer, Otorhinolaryngeal, run by University Hospital, Clermont-Ferrand at 7 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lise Laclautre (334.73.754.963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pharyngocutaneous fistula occurring within 30 days postoperatively (time frame: Day 30). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in